The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1331
Bepotastine (Bepreve) - An Ophthalmic H1-Antihistamine
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Bepotastine besilate 1.5% ophthalmic solution (Bepreve – ISTA Pharmaceuticals), an H1-antihistamine, has been approved by the FDA for topical treatment of itching associated with allergic conjunctivitis in patients ≥2 years old. Bepotastine was first developed in an oral systemic formulation and has been used as such for treatment of allergic rhinitis in Japan.

TREATMENT OF ALLERGIC CONJUNCTIVITIS — Allergic conjunctivitis is the most common form of ocular allergy. The main symptom of itching can be relieved by oral H1-antihistamines such as cetirizine (Zyrtec, and others; available over the counter), desloratadine (Clarinex), fexofenadine (Allegra, and others) or loratadine (Claritin, and others; available over the counter). Ophthalmic antihistamines are also effective and have a more rapid onset of action than the oral drugs. Ketotifen (which is ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Bepotastine (Bepreve) - An Ophthalmic H1-Antihistamine
Article code: 1331c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian